Tag Archives: Johnson & Johnson
Health Perfect Stocks Alert; Gilead Sciences Inc. (NASDAQ:GILD) and Johnson & Johnson’s (NYSE:JNJ)
Johnson & Johnson’s (NYSE:JNJ) Janssen Research & Development LLC reported that the US Food and Drug Administration once more refused the acceptance of its blood thinner Xarelto for patients with a heart problem called as acute coronary syndrome.
The FDA …
Johnson & Johnson’s (NYSE:JNJ) Battling Hard to Stay up with Hip Implants – BPL, COP, JNJ
The operator of petroleum products transmission, gas storage and fuel distribution services, Buckeye Partners L.P.’s (NYSE:BPL)shares were able to eke out gains on Friday after the company reported that its fourth-quarter profit declined 41% as the pipeline storage firm was …
Home Depot Inc. (NYSE:HD) Hiring Labor for Bubbly Spring Season – HD, KO, JNJ, LUV, LOW, UAL, MGM, WAG, M
Home Depot Inc. (NYSE:HD)announced on Wednesday that it is in the course of employing over 80,000 associates for the demanding spring season, which is the firm’s annual peak season.
The firm reported that it would employ 10,000 more spring labors, …
Biogen Idec Inc. (NASDAQ:BIIB) Merging with Elan over Tysabri – BIIB, TEVA, HLF, BIOL, INO, BMY, GNBT, PFE, JNJ
Biogen Idec Inc. (NASDAQ:BIIB) would merge with Elan Corp., its 50-50 associate in a partnership on the multiple-sclerosis drug Tysabri, Elanannounced on Wednesday.
Rules regulations for Biogen Idec, the Weston, Mass., drugmaker, to give Elan $3.25 billion openly and then …
Morgan Stanley (MS) Shatter Merck (NYSE:MRK) Stock Rating after Quarterly Results – MRK, GALE, TEVA, ANTH, JNJ, HEB, BMY, GSK, NVS
Merck & Co., Inc (NYSE:MRK) stock rationing was lower to market perform by Lee rink Swann while Morgan Stanley shatters their rationing to underweight.
Shares of second biggest drug maker in US plunged on Monday in early trading session as …
Merck (NYSE:MRK) Shatters Profit Guidance for Fiscal Year 2013; Fiscal Q4 Net Income Tumbles – MRK, GSK, NVS, BMY, GILD, JNJ, HLF, TEVA, CLSN
The Whitehouse Station, New Jersey-based Merck & Co, Inc’s (NYSE:MRK) current year profit forecasts tumbles as generic rivalry to its best selling medicine Singular will damage results.
The drug giant announced that earnings will be in the range of $3.60 …















